Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer

被引：1
|
作者：
Vigneault, E. [1 ]
Morton, G. [2 ]
Perulekar, W. [3 ]
Niazi, T. [4 ]
Springer, G. [5 ]
Barkati, M. [6 ]
Chung, P. [7 ]
Koll, W. [8 ]
Kamran, A. [9 ]
Montreal, M. [3 ]
Ding, K. [3 ]
Loblaw, A. [2 ]
机构：
[1] CHU Quebec, Hotel Dieu Quebec, Radiat Oncol & Res Ctr, Quebec City, PQ, Canada
[2] Odette Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[3] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[4] Mc Gill Jewish Gen Hosp, Dept Radiat Oncol, Montreal, PQ, Canada
[5] Windsor Reg Hosp, Radiat Oncol, Windsor, ON, Canada
[6] CHUM Hop Notre Dame, Radiat Oncol, Montreal, PQ, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[8] Lakeridge Hosp, Radiat Oncol, Oshawa, ON, Canada
[9] Dr H Bliss Murphy Canc Ctr, Radiat Oncol, St John, NF, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2017年 / 123卷
关键词：
D O I：
10.1016/S0167-8140(17)32136-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1774
引用
收藏
页码：S975 / S976
页数：2
相关论文
共 50 条
  • [31] Intermediate-risk Prostate Cancer: Stratification and Management
    Preisser, Felix
    Cooperberg, Matthew R.
    Crook, Juanita
    Feng, Felix
    Graefen, Markus
    Karakiewicz, Pierre I.
    Klotz, Laurence
    Montironi, Rodolfo
    Nguyen, Paul L.
    D'Amico, Anthony V.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 270 - 280
  • [32] Active surveillance for intermediate-risk prostate cancer
    Nayan, Madhur
    Carvalho, Filipe L. F.
    Feldman, Adam S.
    WORLD JOURNAL OF UROLOGY, 2022, 40 (01) : 79 - 86
  • [33] Active surveillance for intermediate-risk prostate cancer
    Madhur Nayan
    Filipe L. F. Carvalho
    Adam S. Feldman
    World Journal of Urology, 2022, 40 : 79 - 86
  • [34] Stratification of patients with intermediate-risk prostate cancer
    Jung, Jin-Woo
    Lee, Jung Keun
    Hong, Sung Kyu
    Byun, Seok-Soo
    Lee, Sang Eun
    BJU INTERNATIONAL, 2015, 115 (06) : 907 - 912
  • [35] Radiotherapy in low and intermediate-risk prostate cancer
    Yalman, Deniz
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 86 - 91
  • [36] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [37] HDR Brachytherapy boost irradiation in the radiotherapy (RT) of intermediate and high risk localised prostate cancer
    Agoston, P
    Major, T
    Somogyi, A
    Baricza, K
    Szasz, K
    Lövey, J
    Németh, G
    Kasler, M
    Fodor, J
    RADIOTHERAPY AND ONCOLOGY, 2005, 75 : S4 - S5
  • [38] HDR brachytherapy as a boost for intermediate and high risk prostate cancer: Longterm outcome of 2028 implants
    Kurek, R
    Martin, T
    Buhleier, T
    Dannenberg, T
    Baltas, D
    Zamboglou, N
    Tunn, UW
    JOURNAL OF UROLOGY, 2006, 175 (04): : 314 - 314
  • [39] MRI assisted focal boost integrated with HDR monotherapy for low/intermediate risk prostate cancer
    Dalimonte, L.
    Helou, J.
    Morton, G.
    Chung, H.
    McGuffin, M.
    Ravi, A.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S51 - S51
  • [40] Pelvic SABR with HDR boost in intermediate and high risk prostate cancer (spare): early results
    Musunuru, H. B.
    Deabreu, A.
    Davidson, M.
    Ravi, A.
    Hlou, J.
    Ho, L.
    Cheung, P.
    Vesprini, D.
    Liu, S.
    Chu, W.
    Chung, H.
    Zhang, L.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S719 - S719
12345